SCHEMBL1850487

SCHEMBL1850487

O=C(OCc1ccccc1Cl)N1CC=C(c2c[nH]c3ncccc23)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 7/20 0.64
CHEK1 O14757 3/20 0.56
MAP4K4 O95819 3/20 0.56
PIM1 P11309 3/20 0.56
PRKACA P17612 3/20 0.56
CLK2 P49760 3/20 0.56
GSK3B P49841 3/20 0.56
CDK5 Q00535 3/20 0.56
PRKAA1 Q13131 3/20 0.56
ROCK1 Q13464 3/20 0.56
DYRK1A Q13627 3/20 0.56
CLK4 Q9HAZ1 3/20 0.56
CHEK2 O96017 2/20 0.56
PRKCG P05129 2/20 0.56
CDK1 P06493 2/20 0.56
FGFR1 P11362 2/20 0.56
RPS6KB1 P23443 2/20 0.56
CDK2 P24941 2/20 0.56
MARK3 P27448 2/20 0.56
MAPK1 P28482 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1850198 0.87 CHEK1 (0.62) BTKCHEK1MAP4K4PIM1PRKACA
SCHEMBL4053840 0.85 CHEK1 (0.61) BTKCHEK1MAP4K4PIM1PRKACA
SCHEMBL1853760 0.85 CHEK1 (0.62) BTKCHEK1MAP4K4PIM1PRKACA
SCHEMBL18129748 0.82 MAP4K4 (0.58) BTKCHEK1MAP4K4PIM1PRKACA
SCHEMBL18129721 0.81 PRKACA (0.56) BTKCHEK1MAP4K4PIM1PRKACA
SCHEMBL18129543 0.80 PRKACA (0.56) BTKCHEK1MAP4K4PIM1PRKACA
SCHEMBL1848432 0.80 CHEK1 (0.61) BTKCHEK1MAP4K4PIM1PRKACA
SCHEMBL16151126 0.79 BTK (0.81) BTKMAPTLMNA
SCHEMBL2265068 0.78 CHEK1 (0.67) BTKCHEK1MAP4K4PIM1PRKACA
SCHEMBL3601418 0.78 CHEK1 (0.68) BTKCHEK1MAP4K4PIM1PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323659-A1 COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES Abbott Laboratories (US) 2011-05-25 EP claimed
WO-2010017150-A1 COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2010-02-11 WO claimed
US-20100035919-A1 COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2010-02-11 US claimed
EP-2323659-A1 COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES Abbott Laboratories (US) 2011-05-25 EP disclosed
WO-2010017150-A1 COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2010-02-11 WO disclosed
US-20100035919-A1 COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035919-A1 COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES ROCK1, ROCK2, RHOA BTK 294/4885CHEK1 434/4885MAP4K4 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.